Cargando…

ODP014 Safety and Efficacy of IBI362 (LY3305677) 9 mg and 10 mg in Chinese Adults with Overweight or Obesity

BACKGROUND: IBI362, a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, achieved 12-week weight loss up to 6.4% at doses up to 6 mg in Chinese participants with overweight or obesity. We further explored the safety and efficacy of IBI362 dosed up to 9 mg and 10 mg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Linong, Jiang, Hongwei, Yang, Jing, Yu, Lei, Cai, Chenghang, Liu, Meng, Deng, Huan, Feng, Liqi, Qian, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Adipose Tissue, Appetite, & Obesity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624873/ http://dx.doi.org/10.1210/jendso/bvac150.026

Ejemplares similares

FRI014 Exploring The Epigenetic Fingerprint Of Sedentary Behavior
por: Brener, Avivit, et al.
Publicado: (2023)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

ODP009 Obesity-related Conditions in Adults with Overweight and Obesity in the United States: A Cluster Analysis
por: Chiu, Kevin, et al.
Publicado: (2022)

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)
por: Rubino, Domenica M, et al.
Publicado: (2021)

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
por: Kushner, Robert F, et al.
Publicado: (2021)

Safety and Tolerability of Concomitant Administration of Multiple-Dose AM833 With Semaglutide 2.4 MG for Weight Management
por: Enebo, Lone B, et al.
Publicado: (2021)

ODP003 Different Phenotypes of Obesity: Focus on The Intestinal Microbiom and The Adipomyokin Profile
por: Volkova, Natalya, et al.
Publicado: (2022)

ODP606 Long-term Efficacy of Setmelanotide in Patients With Bardet-Biedl Syndrome
por: Argente, Jesús, et al.
Publicado: (2022)

ODP607 Long-term Efficacy of Setmelanotide in Patients With POMC or LEPR Deficiency Obesity
por: Clément, Karine, et al.
Publicado: (2022)

IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study
por: Ji, Linong, et al.
Publicado: (2021)

ODP004 Glucose Profiles and Insulin Sensitivity in Adults with Overweight/Obesity Participating in a Weight Loss Intervention based on Early Time-Restricted Eating plus Daily Caloric Restriction vs Daily Caloric Restriction Alone
por: Jeffers, Rebecca, et al.
Publicado: (2022)

ODP002 ASSOCIATION BETWEEN OBESITY AND DIABETES POTENTIATES RENAL FUNCTION IMPAIRMENT IN BARIATRIC PATIENTS
por: Naliato, Erika
Publicado: (2022)

ODP008 Nonalcoholic Fatty Liver Disease (NAFLD) Impacts Weight Loss after Bariatric Surgery
por: Abu-Rumaileh, Mohammed, et al.
Publicado: (2022)

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)
por: Mosenzon, Ofri, et al.
Publicado: (2021)

ODP591 Obesity and Weight Loss Apps in COVID-19 Era: Do They Help Both the Doctor and the Patient?
por: Lawrence, Rebecca, et al.
Publicado: (2022)

SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

ODP005 Molecular Characterization of Early Adipose Tissue Remodeling and Fibrosis in a Murine Model of Diet-Induced Obesity.
por: Timms, Katie, et al.
Publicado: (2022)

ODP001 AKR1C2 Activity in Abdominal Adipose Tissue of Women with or without Excess Visceral Adiposity
por: Ostinelli, Giada, et al.
Publicado: (2022)

SAT-099 Liraglutide 3.0 mg as an Adjunct to Intensive Behavior Therapy in Individuals with Obesity: SCALE IBT 56-Week Randomized, Double-Blind, Placebo-Controlled Trial
por: Wadden, Thomas, et al.
Publicado: (2019)

SAT-105 Weight Loss As Determined By Adherence To Reduced Caloric Diet, Increased Physical Activity, Liraglutide 3.0 Mg and Placebo: A Sub-analysis Of The SCALE IBT Trial
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

ODP006 Multidisciplinary Weight Management Improves Body Weight And Body Mass Composition In Breast Cancer Women Undergoing Adjuvant Chemotherapy
por: Nguyen, Vivien, et al.
Publicado: (2022)

ODP605 Body Mass Index and Weight Reductions in Patients With SRC1 Genetic Variant Obesity After 1 Year of Setmelanotide
por: Martos-Moreno, Gabriel Á, et al.
Publicado: (2022)

MON-120 Effect of Weight Loss on Physical Function Measured by the 6-Minute Walking Distance Test in Individuals with Obesity: Results from the SCALE IBT Trial of Liraglutide 3.0 Mg
por: Rubino, Domenica, et al.
Publicado: (2019)

ODP010 Relaxin Receptor RXFP1 Knockout in Adipose Tissue Progenitor Cells Results in Resistance to High Fat Diet-Induced Weigh Gain
por: Bennett, Robert, et al.
Publicado: (2022)

ODP007 Nephron Specific ATP6AP2 Knockout Increases Urinary Excretion of Fatty Acids while Decreasing Renal Cortical Megalin Expression
por: Culver, Silas, et al.
Publicado: (2022)

Profile of Intestinal Microbiota and Anxiety Level in Overweight Children and Adolescents
por: Bandeira Farias, Maria Paula Costa, et al.
Publicado: (2021)

Cancer Risk of Patients With Overweight and Obesity: A Predictive Model
por: Turchin, Alexander, et al.
Publicado: (2021)

ODP011 Single Nuclei RNA-Sequencing of Frozen Human Adipose Tissue and PET/CT Imaging Coupled With Deep-Learning Reveals Single-Cell Landscape and Transcriptional Dynamics Related to Adipocyte Hypertrophy and in Vivo Dysmetabolism
por: Ye, Run Zhou, et al.
Publicado: (2022)

SAT-103 Assessing Factors Influencing Eating in Overweight and Obese Individuals
por: DiBenedetti, Dana, et al.
Publicado: (2019)

FRI007 Kisspeptin Does Not Affect Food Intake In Women With Overweight Or Obesity
por: Izzi-Engbeaya, Chioma, et al.
Publicado: (2023)

Neurobiology of Avoidant/Restrictive Food Intake Disorder in Youth With Overweight/Obesity Versus Healthy Weight
por: Liya, Kerem, et al.
Publicado: (2021)

Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study
por: Wilding, John P H, et al.
Publicado: (2021)

SAT659 Prevalence Of Multimorbidity Across Age Groups Among Us Adults With Overweight Or Obesity
por: Ezendu, Kyrian, et al.
Publicado: (2023)

SAT657 Work Loss Among Privately Insured Employees With Overweight And Obesity In The United States
por: Shinde, Shraddha, et al.
Publicado: (2023)

SAT-096 Later Timing of Energy Intake Associates with Higher Fat Mass in Adults with Overweight and Obesity
por: Zaman, Adnin, et al.
Publicado: (2019)

FRI030 The Clinical Significance Of The Oxidative Status Evaluation Among Insulin Resistant Overweight And Obese Patients
por: Popławska-Kita, Anna, et al.
Publicado: (2023)

SAT664 Obesity And Overweight Diagnosis, Physician Prescription And Patient Filling Of Anti-Obesity Medications In US
por: Ezendu, Kyrian, et al.
Publicado: (2023)

SAT-094 Overweight and Obesity Associated with Immune-Related Adverse Events in Patients on Immune Checkpoint Inhibitor Therapy
por: Leiter, Amanda, et al.
Publicado: (2019)

FRI050 A Cross-sectional Study Of Parental Outdoor Play Preferences And Association With Child Overweight And Obesity
por: Gavryutina, Irina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bm6v9jpti9ubir8hcm0q2c1unc